Cephalosporin · Antibiotic
Also known as Ceftazidime pentahydrate
KDIGO 2024 + manufacturer label
493 branded formulations and 180 fixed-dose combinations. Look up specific brands in the Drugs workspace.
Jan Aushadhi — generic available at GoI pharmacies
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-1 and PBP-3. This binding prevents cross-linking of peptidoglycan chains in the bacterial cell wall, leading to osmotic lysis of the bacterial cell. Ceftazidime is distinguished from other third-generation cephalosporins by its enhanced activity against Pseudomonas aeruginosa due to its unique C-7 side chain (pyridinium group) that confers stability against beta-lactamases produced by this organism.
FDA PLLR: Animal studies showed no teratogenicity. Limited human data. Crosses placenta. Generally considered safe in pregnancy (Category B old system).
Excreted in breast milk in low concentrations. Compatible with breastfeeding per AAP. Monitor infant for diarrhea or candidiasis.
Increased risk of acute kidney injury
Monitor renal function closely (serum creatinine, urine output). Adjust doses of both drugs if renal impairment develops. Consider therapeutic drug monitoring for aminoglycosides.
Shared side chain
Avoid if severe ceftazidime allergy
Source: Kimi deep-research + Cla
Synergistic antibacterial activity against Pseudomonas and other gram-negative organisms. Both are nephrotoxic; combined use may increase renal risk.
Monitor renal function daily. Ensure adequate hydration. Synergistic combination is standard for Pseudomonal infections. Consider TDM for aminoglycoside.
Source: Kimi deep-research + Cla
Pharmacodynamic antagonism — chloramphenicol is bacteriostatic while ceftazidime is bactericidal. Concurrent use may reduce bactericidal efficacy.
Avoid concurrent use if possible. If both needed, separate by several hours and monitor clinical response.
Source: Kimi deep-research + Cla
High-dose loop diuretics may increase nephrotoxicity risk when combined with cephalosporins, though less than with aminoglycosides.
Monitor renal function. Ensure adequate hydration. Use lowest effective diuretic dose.
Source: Kimi deep-research + Cla
Enhanced risk of acute kidney injury, especially in patients with pre-existing renal impairment or other nephrotoxic agents.
Monitor renal function closely. Ensure adequate hydration. Consider alternative diuretics if possible, or use with caution and close monitoring.
Increased INR and bleeding risk (though less pronounced than with some other cephalosporins).
Monitor INR closely, especially at the start and end of ceftazidime therapy. Adjust warfarin dose as needed. Educate patient on bleeding signs.
Probenecid competitively inhibits renal tubular secretion of ceftazidime, increasing plasma concentrations and prolonging half-life.
May be used therapeutically to prolong ceftazidime exposure. No routine dose adjustment needed.
Source: Kimi deep-research + Cla
Increased risk of acute kidney injury, particularly in patients with pre-existing renal impairment or prolonged therapy.
Monitor renal function (serum creatinine, BUN, urine output) closely. Consider therapeutic drug monitoring for vancomycin. Adjust doses as needed.
Ceftazidime may reduce vitamin K synthesis by gut flora and/or affect platelet function, potentiating warfarin's anticoagulant effect.
Monitor INR closely (every 2-3 days) when starting or stopping ceftazidime. Anticipate warfarin dose adjustment.
Source: Kimi deep-research + Cla
2 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, Katzung·Verified: 2026-05-18 · House clinical team·Cockpit curated: 2026-05-18